Key Developments: AEterna Zentaris Inc (AEZS.O)

AEZS.O on Consolidated Issue listed on NASDAQ Capital Market

0.59USD
26 Dec 2014
Price Change (% chg)

$0.00 (+0.43%)
Prev Close
$0.59
Open
$0.59
Day's High
$0.59
Day's Low
$0.58
Volume
339,836
Avg. Vol
1,999,344
52-wk High
$1.62
52-wk Low
$0.48

Search Stocks

Latest Key Developments (Source: Significant Developments)

Aeterna Zentaris Inc closes public offering of common shares and warrants
Monday, 25 Nov 2013 11:15am EST 

Aeterna Zentaris Inc:Says the closing of its previously announced public offering of 13.1 million units generating net proceeds of about $13.7 million.Says Canaccord Genuity Inc. acted as the sole book-running manager, and Maxim Group LLC act as co-manager for the Offering.Says it intends to use the net proceeds from the Offering to continue to fund its ongoing drug development activities.  Full Article

Aeterna Zentaris Inc. Announces Pricing of USD15.1 Million Public Offering of Common Shares and Warrants
Wednesday, 20 Nov 2013 08:22am EST 

Aeterna Zentaris Inc. announced the pricing of its previously announced public offering of 13.1 million units (the Offering), with each unit consisting of one common share and one whole warrant to purchase one common share, at a purchase price of USD1.15 per unit. Each warrant will be exercisable for a period of five years following the issuance thereof at an exercise price of USD1.60 per share. Net proceeds from the Offering are expected to be approximately USD13.7 million, after deducting underwriting commissions and other expenses related to the Offering. Canaccord Genuity Inc. is acting as the sole book-running manager for the Offering. Maxim Group LLC acted as co-manager for the Offering. The Offering is expected to close on or about November 25, 2013, subject to customary closing conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approvals of the Toronto Stock Exchange and the NASDAQ Capital Market. The Company intends to use the net proceeds from the Offering to continue to fund its ongoing drug development activities, primarily for the advancement of its zoptarelin doxorubicin (AEZS-108) program, secondly for its macimorelin acetate (AEZS-130) program, including the preparation of its commercial launch, as well as for the potential addition of commercialized products to the Company's pipeline, future negative cash flow, general corporate purposes and working capital.  Full Article

AEterna Zentaris Inc Announces Proposed Public Offering Of Common Shares And Warrants
Tuesday, 19 Nov 2013 04:05pm EST 

Aeterna Zentaris Inc announced that it has commenced an underwritten public offering of units (the "Offering"), consisting of common shares and warrants to purchase common shares. The pricing and number of Units as well as the exercise price and duration of the warrants will be determined in the course of marketing. Canaccord Genuity is acting as sole book-running manager for the proposed Offering.  Full Article

AEterna Zentaris Inc Submits New Drug Application to FDA for Macimorelin Acetate (AEZS-130) for Evaluation of AGHD
Tuesday, 5 Nov 2013 07:30am EST 

Aeterna Zentaris Inc announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for its ghrelin agonist, macimorelin acetate (AEZS-130). Phase 3 data have demonstrated that the compound has the potential to become the first orally-approved product that induces growth hormone release to evaluate adult growth hormone deficiency, with accuracy comparable to available intravenous and intramuscular testing procedures.  Full Article

AEterna Zentaris Inc Completes $7.8 Million Registered Direct Offering
Tuesday, 30 Jul 2013 06:00pm EDT 

AEterna Zentaris Inc announced that it has completed its previously announced registered direct offering of $7.8 million of units comprised of common shares and common share purchase warrants to certain institutional investors. Net proceeds from this offering, after deducting placement agent fees and other offering expenses, total approximately $7 million. All of the securities were offered pursuant to an effective shelf registration statement. Proceeds from the transaction will be used to continue to fund the Company's ongoing drug development activities, primarily for the advancement of its zoptarelin doxorubicin program, secondly for its macimorelin acetate program, as well as for general corporate purposes and working capital. Burrill Securities LLC acted as the exclusive placement agent for the transaction. As of July 30, 2013 and after issuing 5.2million common shares at the closing of this offering, the Company had approximately 31.2 million common shares issued and outstanding, without giving effect to or assuming the exercise of any outstanding warrants.  Full Article

AEterna Zentaris Inc Announces Dismissal Of Class Action Lawsuit
Thursday, 6 Jun 2013 04:05pm EDT 

AEterna Zentaris Inc announced that the previously disclosed purported class action lawsuit filed against the Company and certain of its officers (the Defendants) by Faruqi & Faruqi LLP in the United States District Court for the Southern District of New York has been entirely dismissed with prejudice and without leave to amend. No payment was made by any of the Defendants to the plaintiff or his counsel in connection with the lawsuit. The plaintiff has 30 days from the docketing of the final judgment to file a notice of appeal, if he determines to do so.  Full Article

AEterna Zentaris Inc Announces Transfer Of Manufacturing Rights Related To Cetrotide To Merck KGaA
Wednesday, 17 Apr 2013 07:30am EDT 

AEterna Zentaris Inc announced that its German subsidiary has entered into binding agreements with various partners and licensees with respect to the manufacturing rights and obligations for its Cetrotide product. The principal effect of such agreements is to transfer manufacturing rights and to grant a manufacturing license for Cetrotide to a subsidiary of Merck KGaA of Darmstadt, Germany (Merck Serono), in all jurisdictions. Subject to the satisfaction of customary closing conditions, the transaction is expected to be completed on or about October 1, 2013, at which time Aeterna Zentaris would receive a one-time payment of EUR2.5 million, or approximately $3.2 million and certain other payments. In addition, the Company has also entered into a transitional services agreement with Merck KGaA under which the Company will, during a 36-month period, provide various transition services to assist Merck KGaA in assuming responsibility for the manufacturing of Cetrotide in consideration for the payment of a monthly fee to the Company throughout such period.  Full Article

AEterna Zentaris Inc Announces Appointment Of New President and Chief Executive Officer
Monday, 15 Apr 2013 08:00am EDT 

AEterna Zentaris Inc announced that David A. Dodd has been appointed President and Chief Executive Officer of the Company, succeeding Juergen Engel, PhD. Mr. Dodd has also been appointed director on the Company's Board of Directors. Aeterna Zentaris Inc. is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs.  Full Article

Aeterna hits record low after FDA rejects growth hormone test

- Canada's Aeterna Zentaris Inc said the U.S. Food and Drug Administration rejected macimorelin, which the drugmaker had hoped would be the first orally administered drug to determine if adults had growth hormone deficiency.

Search Stocks